China Medicine(OTC) CHME

China Medicine Corp. is a prominent player in the pharmaceutical industry, specializing in the production and distribution of prescription and over-the-counter drugs, traditional Chinese medicine products, and medical devices. The company operates a comprehensive sales network throughout China, catering to various medical needs.

Products and Services

• Prescription and over-the-counter drugs for various health conditions
• Traditional Chinese medicine products and dietary supplements
• Medical devices and formulations for diverse applications

Growth Outlook

• Strong demand for traditional Chinese medicine supports market expansion
• Increasing healthcare spending in China drives product sales growth
• Strategic partnerships enhance distribution capabilities and market reach

Financial Highlights

• Recent quarterly revenue of 17.55 million USD, showing consistent sales performance
• Trailing twelve months (TTM) net income margin of 2.65%, indicating profitability
• Current ratio of 2.10, reflecting strong liquidity position

China Medicine Corp. has established itself as a significant entity in the healthcare sector, focusing on a diverse range of products that address various medical conditions. The company's commitment to traditional Chinese medicine aligns with growing consumer interest in holistic health solutions. With a robust sales network and strategic growth initiatives, the company is well-positioned to capitalize on the increasing demand for healthcare products in China. Recent financial performance indicates a solid revenue stream, with the latest quarterly results reflecting a revenue of 17.55 million USD. The TTM net income margin of 2.65% demonstrates the company's ability to maintain profitability amidst competitive pressures. Furthermore, a current ratio of 2.10 suggests a strong liquidity position, enabling the company to meet its short-term obligations effectively. Overall, China Medicine Corp. presents a compelling opportunity for investors interested in the pharmaceutical sector, particularly in the context of China's expanding healthcare market. The combination of a diverse product portfolio, strategic growth initiatives, and solid financial performance positions the company favorably for future growth.